Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A C Ford

Showing results (11-20 of 91) with videos related to

Pageof 10
Sort By:
Alimentary Pharmacology & Therapeutics|June 19, 2012
Letter: the effects of overlapping symptoms on the response to PPI therapy in GERDM Kennedy, A C Ford
Alimentary Pharmacology & Therapeutics|April 24, 2010
Meta-analysis: factors affecting placebo response rate in the irritable bowel syndromeA C Ford, P Moayyedi
Neurogastroenterology and Motility|April 24, 2015
Irritable bowel syndrome and somatizationP Patel, A C Ford
Alimentary Pharmacology & Therapeutics|March 18, 2015
Letter: irritable bowel syndrome is significantly associated with somatisation - authors' replyP Patel, A C Ford
Alimentary Pharmacology & Therapeutics|December 16, 2010
Defining a responder in treatment trials for chronic idiopathic constipationS Raja, A C Ford
Alimentary Pharmacology & Therapeutics|January 12, 2017
Editorial: volatile organic compounds in irritable bowel syndrome - technology for an accurate and reliable point-of-care test?R Sood, A C Ford
Alimentary Pharmacology & Therapeutics|May 6, 2015
Efficacy of hypnotherapy in one thousand patients with irritable bowel syndromeS Dube, A C Ford
Neurogastroenterology and Motility|September 3, 2015
Clinical and epidemiological differences in functional dyspepsia between the East and the WestS Mahadeva, A C Ford
Neurogastroenterology and Motility|January 3, 2013
Balancing risks and benefits of prucalopride for the treatment of chronic constipation in AsiansS A Morais, A C Ford
Alimentary Pharmacology & Therapeutics|July 15, 2017
Editorial: mesalazine to prevent recurrent acute diverticulitis-the final nail in the coffinD J Gracie, A C Ford
Pageof 10

Showing results (11-20 of 91) with videos related to

Sort By:
Pageof 10
Alimentary Pharmacology & Therapeutics|June 19, 2012
Letter: the effects of overlapping symptoms on the response to PPI therapy in GERDM Kennedy, A C Ford
Alimentary Pharmacology & Therapeutics|April 24, 2010
Meta-analysis: factors affecting placebo response rate in the irritable bowel syndromeA C Ford, P Moayyedi
Neurogastroenterology and Motility|April 24, 2015
Irritable bowel syndrome and somatizationP Patel, A C Ford
Alimentary Pharmacology & Therapeutics|March 18, 2015
Letter: irritable bowel syndrome is significantly associated with somatisation - authors' replyP Patel, A C Ford
Alimentary Pharmacology & Therapeutics|December 16, 2010
Defining a responder in treatment trials for chronic idiopathic constipationS Raja, A C Ford
Alimentary Pharmacology & Therapeutics|January 12, 2017
Editorial: volatile organic compounds in irritable bowel syndrome - technology for an accurate and reliable point-of-care test?R Sood, A C Ford
Alimentary Pharmacology & Therapeutics|May 6, 2015
Efficacy of hypnotherapy in one thousand patients with irritable bowel syndromeS Dube, A C Ford
Neurogastroenterology and Motility|September 3, 2015
Clinical and epidemiological differences in functional dyspepsia between the East and the WestS Mahadeva, A C Ford
Neurogastroenterology and Motility|January 3, 2013
Balancing risks and benefits of prucalopride for the treatment of chronic constipation in AsiansS A Morais, A C Ford
Alimentary Pharmacology & Therapeutics|July 15, 2017
Editorial: mesalazine to prevent recurrent acute diverticulitis-the final nail in the coffinD J Gracie, A C Ford
Pageof 10